Payment overview · 2025
General Payments
$355.48
23 reported records · 6 companies
Healthcare provider profile · identity verified
Robert N Galbut, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · MIAMI BEACH, FL · NPI 1730295486
Verified facts
What the public records show
CMS Open Payments records show Robert N Galbut, M.D. received $355.48 in general payments during 2025 across 23 reported records.
Verona Pharma, Inc. accounted for 45.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $161.38 | 45.4% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $104.26 | 29.3% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $25.31 | 7.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.90 | 7.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.81 | 6.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.82 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $355.48 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $161.38 | 14 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $104.26 | 5 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $25.31 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 100 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 178 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
178 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 284 | 126 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 57 |
| Montelukast Sodium | Montelukast Sodium | 182 | 65 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 178 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 43 |
| Azithromycin | Azithromycin | 162 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 129 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 112 | 36 |
| Eliquis | Apixaban | 100 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 32 |
| Lisinopril | Lisinopril | 87 | 21 |
| Losartan Potassium | Losartan Potassium | 82 | 28 |
| Furosemide | Furosemide | 81 | 37 |
| Ventolin Hfa | Albuterol Sulfate | 75 | 20 |
| Famotidine | Famotidine | 72 | 33 |
| Breo Ellipta | Fluticasone/Vilanterol | 70 | 19 |
| Metformin Hcl | Metformin Hcl | 64 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 63 | 27 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 61 | 21 |
| Alprazolam | Alprazolam | 60 | 16 |
| Ezetimibe | Ezetimibe | 53 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 15 |
| Mirtazapine | Mirtazapine | 51 | 11 |
| Omeprazole | Omeprazole | 49 | 14 |
| Lorazepam | Lorazepam | 45 | 11 |
| Donepezil Hcl | Donepezil Hcl | 44 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 42 | 15 |
| Gabapentin | Gabapentin | 41 | 15 |
| Meloxicam | Meloxicam | 41 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Simvastatin | Simvastatin | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 24 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | 11 |
| Levofloxacin | Levofloxacin | 26 | 21 |
| Meclizine Hcl | Meclizine Hcl | 26 | 14 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 14 |
| Torsemide | Torsemide | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Lunesta | Eszopiclone | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $355.48 · 23 records | Verona Pharma, Inc. | BREZTRI, DUPIXENT, ELIQUIS, NURTEC ODT, OFEV, Ohtuvayre, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error